1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977.
2. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304.
3. Job D, Eshwege E, Guyot-Argenton C, et al. Effect of multiple daily insulin injection on the course of retinopathy. Diabetes 1976;25: 463.
4. Lauritzen T, Frost-Larsen K, Larsen HW, et al. Steno Study Group: two year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985;34(suppl 3):74.
5. Deckert T, Lauritzen T, Parving H, et al. Steno Study Group: effect of two years of strict metabolic control on kidney function in long-term insulin dependent-diabetics. Diabetic Nephropathy 1983;2:6.
6. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986;2:1300.
7. Dahl-Jorgensen K, Brichmann-Hanssen O, Hanssen KF, et al. Effect of near normoglycemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo Study. BMJ 1986;293:1194.
8. Rosenstock J, Friberg T, Raskin P. The effect of glycemic control on the microvascular complications in patients with type I diabetes mellitus. Am J Med 1986;81:1012.
9. Raskin P, Pietri A, Unger R, et al. The effect of diabetic control on skeletal muscle capillary basement membrane width in patients with type I diabetes mellitus. N Engl J Med 1983;309:1546.
10. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988;319:140.
11. Engerman R, Bloodworth JMB, Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1977;26:760.
12. Mauer SM, Steffes MW, Sutherland DER, et al. Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes 1975;24:280.
13. Johnsson SL. Retinopathy and nephropathy in diabetes mellitus: comparison of the effect of two forms of treatment. Diabetes 1960;9:1.
14. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Metab 1977;3:97.
15. Eschwege E, Richard JL, Thibult N, et al. Coronary heart diseased mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res 1985;15(suppl):41.
16. Hostetter MK. Handicaps to host defenses: effect of hyperglycemia on C3 and Candida albicans. Diabetes 1990;39:271.
17. Rayfield EJ, Ault MJ, Keusch GT, et al. Infection and diabetes: the case for glucose control. Am J Med 1982;72:439.
18. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28:119.
19. Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983;71:1544.
20. Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037.
21. Leahy JL, Cooper HE, Weir GC. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. J Clin Invest 1986;77:908.
22. Leahy JL, Bonner-Weir S, Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 1988;81:1407.
23. Robertson RP. Type II diabetes, glucose “non-sense,” and islet cell desensitization. Diabetes 1989;38:1501.
24. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510.
25. Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 1987;36:892.
26. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610.
27. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992;13:415.
28. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent feature of insulin dependent diabetes. Diabetes 1982;31:795.
29. Yki-Jarvinen, Koivisto VA. Natural history of insulin resistance in type I diabetes. N Engl J Med 1986;315:224.
30. Himsworth HP, Kerr RB. Insulin-sensitive types of diabetes mellitus. Clin Sci 1942;4:120.
31. DeFronzo RA, Diebert D, Hendler R, et al. Insulin sensitivity and insulin binding in maturity onset diabetes. J Clin Invest 1979;63: 939.
32. Kolterman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Invest 1981;68:957.
33. Rizza RA, Mandarino LJ, Gerich JE. Mechanism and significance of insulin resistance in noninsulin-dependent diabetes mellitus. Diabetes 1981;30:990.
34. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin dependent (type II) diabetes mellitus. J Clin Invest 1985;76:149.
35. Kobberling J, Tillil H. Empirical risk figures for first-degree relatives of non-insulin-dependent diabetics. In: Kobberling J, Tsttersal R, eds. The genetics of diabetes mellitus. London: Academic, 1982:201.
36. Newman B, Selby JV, King MC, et al. Concordance for type 2 (non–insulin-dependent) diabetes mellitus in male twins. Diabetologia 1987;30:763.
37. Barner AH, Eff C, Leslie RD, et al. Diabetes in identical twins: a study of 2 pairs. Diabetologia 1981;20:87.
38. Lillioja S, Mott DM, Zawadski JK, et al. In vivo insulin action is a familial characteristic in nondiabetic Pima Indians. Diabetes 1987;36: 1329.
39. Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988;4:515.
40. Eriksson J, Franssila-Kallunki A, Edstrand A, et al. Early metabolic defects in persons at increased risk of non–insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337.
41. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscle in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1992;89:782.
42. Gulli G, Ferrannini E, Stern M, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992;41:1575.
43. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of insulin-independent and non–insulin-dependent diabetes. Diabetologia 1982;23:313.
44. Beck-Nielsen H, Richelsen B, Hasling C, et al. Improved in vivo insulin effect during continuous subcutaneous insulin infusion in patients with IDDM. Diabetes 1984;33:832.
45. Yki-Jarvinen H, Koivisto VA. Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type I diabetes. J Clin Endocrinol Metab 1984;58:659.
46. Yki-Jarvinen H, Koivisto VA. Insulin sensitivity in newly diagnosed type I diabetics after ketoacidosis and after three months of insulin therapy. J Clin Endocrinol Metab 1984;59:371.
47. Lager I, Lonnroth P, Von Schenck H, et al. Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. BMJ 1983;287:1001.
48. Kurszynska YT, Petranyi G, Home PD, et al. Muscle enzyme activity and insulin sensitivity in type I (insulin-dependent) diabetes mellitus. Diabetologia 1986;29:699.
49. Gray RS, Cowan P, Duncan LJP, et al. Reversal of insulin resistance in type I diabetes following initiation of insulin treatment. Diabet Med 1986;3:18.
50. Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985;34:222.
51. Foley J, Kashiwagi A, Verso MA, et al. Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-dependent diabetics. J Clin Invest 1983;72:1901.
52. Nankervis A, Proietto J, Aitken P, et al. Differential effects of insulin therapy on hepatic and peripheral insulin sensitivity in type 2 (non–insulin-dependent) diabetes. Diabetologia 1982;23:320.
53. Greenfield M, Lardinois C, Doberne L, et al. Metabolic effects of intensive insulin therapy in patients with non-insulin-dependent diabetes (NIDDM). Diabetes 1982;31(suppl 2):58A.
54. Andrews WJ, Vasquez B, Nagulesparan M, et al. Insulin therapy in obese, non–insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984;33:634.
55. Scarlett JA, Garvey RS, Griffin J, et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 1982;5: 353.
56. Gormley MJJ, Hadden DR, Woods R, et al. One month’s insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal. Metabolism 1986;35:1029.
57. Hidaka H, Nagulesparan M, Klimes I, et al. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J Clin Endocrinol Metab 1982;54: 217.
58. Scarlett JA, Kolterman OG, Ciaraldi TP, et al. Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus. J Clin Endocrinol Metab 1983;56: 1195.
59. Savage PJ, Bennion LO, Flock EV, et al. Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. J Clin Endocrinol Metab 1979; 48:999.
60. Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985;61:917.
61. Henry RR, Wiest-Kent TA, Scheaffer L, et al. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes 1986;35:155.
62. Nagulesparan N, Savage PJ, Bennion LJ, et al. Diminished effect of caloric restriction on control of hyperglycemia with increasing duration of type II diabetes mellitus. J Clin Endocrinol Metab 1981;53:560.
63. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non–insulin dependent diabetes mellitus. Diabetes 1986;35:990.
64. Beck-Nielsen H, Pedersen O, Sorensen NS. Effects of dietary changes on cellular insulin binding and in vivo insulin sensitivity. Metabolism 1980;29:482.
65. Laakso M, Uusitupa M, Takala J, et al. Effects of hypocaloric diet and insulin therapy on metabolic control and mechanisms of hyperglycemia in obese non–insulin-dependent diabetic subjects. Metabolism 1988;37:1092.
66. Zawadski JK, Bogardus C, Foley JE. Insulin action in obese non–insulin-dependent diabetics and in their isolated adipocytes before and after weight loss. Diabetes 1987;36:227.
67. Walshe K, Andrews WJ, Sheridan B, et al. Three months energy restricted diet does not induce peripheral insulin resistance in new diagnosed non insulin dependent diabetics. Horm Metabol Res 1987; 19:197.
68. Kolterman OG, Grag RS, Shapiro G, et al. The acute and chronic effects of sulfonylurea therapy in type II diabetes. Diabetes 1984; 33:346.
69. Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin on insulin action in patients with non–insulin-dependent diabetes mellitus. N Engl J Med 1986;314:1280.
70. Mandarino LJ, Gerich JE. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non–insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues. Diabetes Care 1984;7(suppl 1):89.
71. Simonson DC, Ferrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984;33:838.
72. Groop L, Schalin C, Franssila-Kalolunki A, et al. Characteristics of non-insulin dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989;87:183.
73. Castillo M, Scheen AJ, Paolisso G, et al. The addition of glipizide to insulin therapy in type II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol (Copenhagen) 1987;116:364.
74. Yki-Jarvinen H, Nikkila E, Eero H, et al. Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. Am J Med 1988; 84:185.
75. Hollenbeck CB, Chen Y-DI, Reaven GM. A comparison of the relative effects of obesity and non–insulin-dependent diabetes mellitus on in vivo insulin-stimulated glucose utilization. Diabetes 1984;33: 622.
76. Garvey WT, Olefsky JM, Marshall S. Insulin receptor down-regulation is linked to an insulin-induced postreceptor defect in the glucose transport system in rat adipocytes. J Clin Invest 1985;76:22.
77. Rizza RA, Mandarino LJ, Genest J, et al. Production of insulin resistance by hyperinsulinemia in man. Diabetologia 1985;28:70.
78. Reaven GM, Sageman WS, Swenson RS. Development of insulin resistance in normal dogs following alloxan-induced insulin deficiency. Diabetologia 1977;13:459.
79. Dall’Aglio E, Chang H, Hollenbeck CB, et al. In vivo and in vitro resistance to maximal insulin stimulated glucose disposal in insulin deficiency. Am J Physiol 1985;249:E312.
80. Bevilacqua S, Barrett EJ, Smith D, et al. Hepatic and peripheral insulin resistance following streptozotocin-induced insulin deficiency in the dog. Metabolism 1985;34:817.
81. Rossetti L, Giaccari A. Relative contribution of glycogen synthesis and glycolysis to insulin-mediated glucose uptake. A dose-response euglycemic clamp study in normal and diabetic rats. J Clin Invest 1990;85:1785.
82. Rossetti L, Hu M. Skeletal muscle glycogenolysis is more sensitive to insulin than is glucose transport/phosphorylation. Relation to the insulin-induced inhibition of hepatic glucose production. J Clin Invest 1993;92:2963.
83. Levy J, Gavin JR III, Fausto A, et al. Impaired insulin action in rats with non-insulin dependent diabetes. Diabetes 1984;33:901.
84. Kurszynska YT, Home PD. Liver and muscle insulin sensitivity, glycogen concentration, and glycogen synthase activity in a rat model of non-insulin dependent diabetes. Diabetologia 1988;31: 304.
85. Kahn BB, Shulman GI, DeFronzo RA, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991;87:561.
86. Hager SR, Jochen AL, Kalkhoff RK. Insulin resistance in normal rats infused with glucose for 72h. Am J Physiol 1991;260:E353.
87. Richter EA, Hansen BF, Hansen SA. Glucose-induced insulin resistance of skeletal muscle glucose transport and uptake. Biochem J 1988;252:733.
88. Richter EA, Hansen SA, Hansen BF. Mechanisms limiting glycogen storage in muscle during prolonged insulin stimulation. Am J Physiol 1988;255:E621.
89. Hansen BF, Hansen SA, Ploug T, et al. Effects of glucose and insulin on development of impaired insulin action in muscle. Am J Physiol 1992;262:E440.
90. Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type 1 diabetes. Diabetes 1987;36:892.
91. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyperglycemia-induced insulin resistance in whole body and skeletal muscle of type 1 diabetic patients. Diabetes 1992;41:571.
92. Fowelin J, Attvall S, Von Schenck H, et al. Effect of prolonged hyperglycemia on growth hormone levels and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism 1993;42:387.
93. Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037.
94. Rossetti L, Laughlin MR. Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 1989;84:892.
95. Karnieli E, Hissin PJ, Simpson IA, et al. A possible mechanism of insulin resistance in the rat adipose cell in streptozotocin-induced diabetes mellitus: depletion of intracellular glucose transport systems. J Clin Invest 1981;68:811.
96. Kasuga MY, Akanuma Y, Iwamoto K, et al. Insulin binding and glucose metabolism in adipocytes from streptozotocin-diabetic rats. Am J Physiol 1978;235:E175.
97. Kobayashi M, Olefsky JM. Effects of streptozotocin-induced diabetes on insulin binding, glucose transport, and intracellular glucose metabolism in isolated rat adipocytes. Diabetes 1979;28:87.
98. Dohm GL, Tapscott EB, Pories WJ, et al. An in vitro human muscle preparation suitable for metabolic studies: decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest 1988;82:486.
99. Garvey WT, Huecksteadt TP, Matthaei S, et al. Role of glucose transporters in the cellular insulin resistance of type II non–insulin-dependent diabetes mellitus. J Clin Invest 1988;81:1528.
100. Haspal HC, Vilk EW, Birnbaum MT, et al. Glucose deprivation and hexose transporter polypeptides of murine fibroblasts. J Biol Chem 1986;261:6778.
101. Van Putten JPM, Krans HMJ. Glucose as a regulator of insulin-sensitive hexose uptake in 3T3 adipocytes. J Biol Chem 1985;260:7996.
102. Sasson S, Cerasi E. Substrate regulation of the glucose transport system in rat skeletal muscle. J Biol Chem 1986;261:16827.
103. Garvey WT, Olefsky JM, Matthaei S, et al. Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes: a new mechanism of insulin resistance. J Biol Chem 1987;262:189.
104. Sasson S, Edelson D, Cerasi E. In vitro autoregulation of glucose utilization in rat soleus muscle. Diabetes 1987;36:1041.
105. Kletzien RF, Perdue JF. Induction of sugar transport in chick embryo fibroblasts by hexose starvation: evidence for transcriptional regulation of transport. J Biol Chem 1985;250:593.
106. Ullrey D, Gammon BMT, Kalckar HM. Uptake patterns and transport enhancements in cultures of hamster cells deprived of carbohydrates. Arch Biochem Biophys 1975;167:410.
107. Ullrey DB, Kalckar HM. The nature of regulation of hexose transport in cultured mammalian fibroblasts: aerobic “repressive” control by D-glucosamine. Arch Biochem Biophys 1981;209:168.
108. Traxinger RR, Marshall S. Recovery of maximal insulin responsiveness after induction of insulin resistance. J Biol Chem 1989;264: 8156.
109. Marshall S, Garvey WT, Traxinger RR. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J 1991;5:3031.
110. Crettaz M, Prentky M, Zaninetti D, et al. Insulin resistance in soleus muscle from obese Zucker rats. Biochem J 1980;186:525.
111. Berger M, Hagg SA, Goodman MN, et al. Glucose metabolism in perfused skeletal muscle. Biochem J 1976;158:191.
112. Charron MJ, Kahn BB. Divergent molecular mechanisms for insulin resistant glucose transport in muscle and adipose cells in vivo. J Biol Chem 1990;265:7994.
113. Kahn BB, Rossetti L, Lodish HF, Charron MJ. Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle. J Clin Invest 1991;87:2197.
114. Garvey WT, Huecksteadt TP, Birnbaum MT. Pretranslational suppression of an insulin-responsive glucose transporter in rats with diabetes mellitus. Science 1989;245:60.
115. Sivitz WI, DeSautel SL, Kayano T, et al. Regulation of glucose transporter messenger RNA in insulin-deficient states. Nature 1989; 340:72.
116. Berger JC, Biswas P, Vicario P, et al. Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting. Nature 1989;340:70.
117. Kahn BB, Charron MJ, Lodish HF, et al. Differential regulation of two glucose transporters in adipose cells from diabetic and insulin treated diabetic rats. J Clin Invest 1989;84:404.
118. Sivitz WI, DeSautel SL, Kayano T, et al. Regulation of glucose transporter messenger RNA levels in rat adipose tissue by insulin. Mol Endocrinol 1990;4:583.
119. Kahn BB, Flier JS. Regulation of glucose transporter gene expression in vivo and in vitro glucose. Diabetes Care 1991;87:561.
120. Dimitrakoudis D, Ramlal T, Rastogi S, et al. Glycemia regulates the glucose transporter number in the plasma membrane of the rat skeletal muscle. Biochem J 1992;284:341.
121. Cordera R, Andraghetti G, DeFronzo RA, et al. Effect of in vivo vanadate treatment on insulin receptor tyrosine kinase activity in partially pancreatectomized diabetic rats. Endocrinology 1990;126: 2177.
122. Marshall S, Monzon R. Amino acid regulation of insulin action in isolated adipocytes. J Biol Chem 1989;264:2037.
123. Marshall S. Kinetics of insulin action on protein synthesis in isolated adipocytes: ability of glucose to selectively desensitize the glucose transport system without altering insulin stimulation of protein synthesis. J Biol Chem 1989;264:2029.
124. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating desensitization of the glucose transport system: role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1992;266:4706.
125. Traxinger RR, Marshall S. Role of aminoacids in modulating glucose-induced desensitization of the glucose transport system. J Biol Chem 1989;264:20910.
126. Traxinger RR, Marshall S. Insulin regulation of pyruvate kinase activity in isolated adipocytes: crucial role of glucose and the hexosamine biosynthesis pathway in the expression of insulin action. J Biol Chem 1992;267:9718.
127. Robinson KA, Sens DA, Buse MG. Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Diabetes 1993;42:1333.
128. Crook ED, Daniels MC, Smith TM, et al. Regulation of insulin-stimulated glycogen synthase activity by overexpression of glutamine:fructose-6-phosphate amidotransferase in rat-1 fibroblasts. Diabetes 1993;42:1289.
129. Rossetti L, Hawkins M, Chen W, et al. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 1995;96:132.
130. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785.
131. Ruderman NB, Saha AK, Vavvas D, et al. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 1999;276:E1.
132. Hawkins M, Barzilai N, Hu M, et al. Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 1997;99: 2173.
133. Hawkins M, Angelov I, Liu R, et al. The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem 1997;272: 4889.
134. Baron A, Zhu J-S, Zhu J-H, et al. Glucosamine induces insulin resistance in vivo by affecting GLUT4 translocation in skeletal muscle. J Clin Invest 1995;96:2792.
135. Hebert L, Daniels M, Zhou J, et al. Overexpression of glutamine: fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 1996;98:930.
136. Cooksey RC, Hebert E, Zhu J-H, et al. Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Endocrinology 1999;140:1151.
137. Pillay TS, Xiao S, Olefsky JM. Glucose-induced phosphorylation of the insulin receptor. J Clin Invest 1996;97:613.
138. Filippis A, Clark S, Proietto J. Increased flux through the hexosamine biosynthesis pathway inhibits glucose transport acutely by activation of protein kinase C. Biochem J 1997;324:978.